OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis
Huseyin Naci, Peter J. Murphy, Beth Woods, et al.
The Lancet (2024) Vol. 405, Iss. 10472, pp. 50-60
Open Access | Times Cited: 8
Huseyin Naci, Peter J. Murphy, Beth Woods, et al.
The Lancet (2024) Vol. 405, Iss. 10472, pp. 50-60
Open Access | Times Cited: 8
Showing 8 citing articles:
Diagnostics and Therapeutics in Ophthalmology
Andreas Arnold‐Vangsted, Yousif Subhi
Journal of Personalized Medicine (2025) Vol. 15, Iss. 1, pp. 28-28
Open Access
Andreas Arnold‐Vangsted, Yousif Subhi
Journal of Personalized Medicine (2025) Vol. 15, Iss. 1, pp. 28-28
Open Access
Re: ‘The relative effectiveness of a high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccines in older adults in France: a retrospective cohort study during the 2021-22 influenza season’ by Bricout et al.
Alain Braillon
Clinical Microbiology and Infection (2025)
Closed Access
Alain Braillon
Clinical Microbiology and Infection (2025)
Closed Access
The UK's Early Access to Medicines Scheme 10 years on: an evaluation using publicly available data
Pandora Pound, Rebecca Ram, Kathy Archibald
JRSM Open (2025) Vol. 16, Iss. 2
Open Access
Pandora Pound, Rebecca Ram, Kathy Archibald
JRSM Open (2025) Vol. 16, Iss. 2
Open Access
Paying the price
David Phizackerley
Drug and Therapeutics Bulletin (2025) Vol. 63, Iss. 3, pp. 34-34
Closed Access
David Phizackerley
Drug and Therapeutics Bulletin (2025) Vol. 63, Iss. 3, pp. 34-34
Closed Access
The opportunity cost of funding new medicines: an attempt to measure the invisible
Laura Vallejo‐Torres, David J. Vanness, Mike Paulden, et al.
Gaceta Sanitaria (2025) Vol. 39, pp. 102460-102460
Open Access
Laura Vallejo‐Torres, David J. Vanness, Mike Paulden, et al.
Gaceta Sanitaria (2025) Vol. 39, pp. 102460-102460
Open Access
Diagnosing and defining obesity
Oliver Mytton, Denise Campbell‐Scherer, Ian Reckless, et al.
BMJ (2025), pp. r460-r460
Closed Access
Oliver Mytton, Denise Campbell‐Scherer, Ian Reckless, et al.
BMJ (2025), pp. r460-r460
Closed Access
Characteristics of Professional Society Oncological Drug Evaluation in the Netherlands from 2016 to 2020: A Retrospective Analysis
Penninx BMF, Michael Samson, AJ Duits, et al.
Journal of Cancer Policy (2025), pp. 100578-100578
Closed Access
Penninx BMF, Michael Samson, AJ Duits, et al.
Journal of Cancer Policy (2025), pp. 100578-100578
Closed Access
Artificial intelligence risks becoming an environmental disaster
Alexander Mafi, Sarah-Lindsay Holmes
BMJ (2025), pp. r505-r505
Closed Access
Alexander Mafi, Sarah-Lindsay Holmes
BMJ (2025), pp. r505-r505
Closed Access
What price is society willing to pay for new drugs?
Victoria Charlton
The Lancet (2024)
Closed Access | Times Cited: 1
Victoria Charlton
The Lancet (2024)
Closed Access | Times Cited: 1
Cost of new drugs does not always justify benefits, say researchers
Elisabeth Mahase
BMJ (2024), pp. q2818-q2818
Closed Access
Elisabeth Mahase
BMJ (2024), pp. q2818-q2818
Closed Access
